Phase 3Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 15,374 enrolled
- Conditions
- Obesity; Overweight
- Interventions
- Tirzepatide; Placebo
- Ages
- adults, older adults
- Registry
- NCT05556512, CTIS2022-501744-15-00
Full record on ClinicalTrials.gov
From the registry
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Primary outcomes
- Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)
History
Primary completion expected
Last registry update
Started
Registered
Papers citing this trial
- Hypertension in young adults with obesity: new mechanisms and therapeutic options
Polish archives of internal medicine
- Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)
ADA Scientific Sessions 2025 abstract
In the news
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Resistance training cuts lean mass loss 25% during tirzepatide obesity treatment
In a 40-week randomized trial of 120 adults aged 50–70, three weekly sessions increased strength 10%, versus a 10% decline with tirzepatide alone, researchers report.
Also in Nature Medicine (opens Nature Medicine in a new tab)
